<DOC>
	<DOCNO>NCT00379431</DOCNO>
	<brief_summary>Rituximab 1000 mg i.v . give day 1 15 , week 26 - 28 , together corticosteroid regimen consist methylprednisolone 100 mg i.v . 30 minute prior infusion .</brief_summary>
	<brief_title>A Protocol Based Treatment Early Severe Systemic Sclerosis With ( Anti-CD20 ) , Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Scleroderma , Systemic</mesh_term>
	<mesh_term>Scleroderma , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>male female &gt; = 18 year SSc accord ARA criterion systemic sclerosis Disease duration le 4 year ( appearance skin change ( oedema , fibrosis ) Inadequate response methotrexate ( least 12 week 10 mg/w , except tolerated Antibodies specific systemic sclerosis : antitopoisomerase ; anticentromere antibody Severe disease define either one following : modify Rodnan skin score ( TSS° &gt; = 14 ) , disease activity score &gt; = 3 Contraception woman childbearing potential . Sexual abstinence alternative contraception . Patient sign informed consent . disease duration 4 year FVC &lt; = 50 % LVEF &lt; = 40 % predict value DLCO &lt; = 40 % predict value Lack peripheral venous access Pregnancy breast feeding Significant cardiac pulmonary disease ( include obstructive pulmonary disease ) , evidence significant uncontrolled concomitant disease , limited , nervous system , renal , hepatic , endocrine gastrointestinal disorder , investigator 's opinion , would preclude patient participation Primary secondary immunodeficiency ( history , currently active ) , include know history HIV infection . Known active infection kind ( exclude fungal infection mail bed ) , major episode infection require hospitalization treatment i.v . antiinfectives within 4 week baseline completion oral antiinfectives within 2 week prior baseline . History deep space/tissue infection ( e.g . fasciitis , abscess , osteomyelitis ) within 52 week prior baseline . History serious recurrent chronic infection ( screen chest infection chest radiograph perform screen perform within 12 week prior screen ) . History cancer , include solid tumor , hematologic malignancy carcinoma situ ( except basal cell squamous cell carcinoma skin excise cure ) . History severe allergic anaphylactic reaction biologic agent know hypersensitivity component rituximab murine protein . Concurrent treatment biologic agent DMARD MTX . Treatment must discontinue 14 day prior baseline , except follow : azathioprine ≥ 28 day ; leflunomide ≥ 8 week ( ≥ 14 day 11 day standard cholestyramine activate charcoal washout ) ; infliximab ≥ 8 week ; adalimumab ≥ week . Previous treatment &gt; 1 biological agent . Previous treatment cell deplete therapy , include investigational agent . Treatment investigational agent within 28 day baseline 5 halflives investigational drug ( xhich ever longer ) . Receipt vaccine within 28 day prior baseline Intolerance contraindication i.v . glucocorticoid . Positive serum human chorionic gonadotropin ( hCG ) measure screen positive pregnancy test prior first rituximab infusion . Positive test hepatitis B surface antigen ( HBsAg ) , hepatitis B core antibody ( HBcAb ) hepatitis C serology . Hemoglobin &lt; 8.0 g/dL . Concentrations serum IgG and/or IgM 5.0 0.40 mg/mL , respectively . Absolute neutrophil count ( ANC ) &lt; 1.5 X 10³/µL .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>